There is increasing concern about abuse of propofol, a widely-used surgical anesthetic and sedative that is currently not a controlled substance. The purpose of this study was to establish a rat model of the psychoactive effect of subanesthetic doses of propofol that could be useful for confirming abuse liability and for studying mechanisms of propofol abuse. Sprague-Dawley rats were trained to discriminate propofol (10 mg/kg, intraperitoneally) from vehicle (2% methylcellulose). Carisoprodol (100 mg/kg), chlordiazepoxide (10 mg/kg), and dizocilpine (0.1 mg/kg) were tested for substitution for the discriminative-stimulus effects of propofol (10 mg/kg), whereas pentylenetetrazol (10 mg/kg) was tested for antagonism of the discriminative-stimulus effects. Propofol (10 mg/kg) was tested for substitution in rats trained to discriminate carisoprodol from vehicle. Carisoprodol produced 59% propofol-appropriate responding, chlordiazepoxide produced 65% propofol-appropriate responding, and dizocilpine produced 34% propofolappropriate responding. Pentylenetetrazol decreased propofol-appropriate responding to 41%. Propofol produced 52% carisoprodol-appropriate responding. Mortality rate during training of propofol (10 mg/kg) was 38%. Postmortem examination revealed cardiovascular abnormalities similar to those observed in propofol-infusion syndrome in humans. The results demonstrate that propofol can be trained as a discriminative stimulus. Its discriminative-stimulus effects were more similar to compounds promoting c-aminobutyric acid-A receptor activity than to a compound inhibiting N-methyl-d-aspartate receptor activity. As propofol has discriminative-stimulus effects similar to known drugs of abuse, and occasions a high-mortality rate, its potential for continued abuse is of particular concern.
Introduction
Propofol has attracted increasing concern about its safety and abuse potential. A recent study (Wilson et al., 2010) concluded that propofol should be scheduled as a controlled substance at the federal level. Animal studies have tended to confirm the abuse potential of propofol, though the results have been equivocal. Propofol can induce conditioned place preference (Pain et al., 1996 (Pain et al., , 1997 and was self-administered by some subjects in studies of rats and baboons (Weerts et al., 1999; LeSage et al., 2000) . In contrast, a study using mice reported that propofol was not self-administered (Blokhina et al., 2004) . In a human study, six of 12 people chose to receive propofol, and preference was directly related to whether these subjects reported pleasant subjective effects after propofol administration (Zacny et al., 1993) .
The purpose of these studies was to determine whether nonsedating doses of propofol produce a discriminative stimulus and to assess potential pharmacological mechanisms for this effect. Propofol has not been previously trained as a discriminative stimulus, although a drugdiscrimination approach (Colpaert, 1999) was thought to be particularly applicable in light of self-administration studies that did not show unequivocal evidence that propofol was reinforcing in all subjects, and the observa-tion that the subjective qualities of propofol appear to determine drug taking in humans (Zacny et al., 1993) . The locomotor depressant effects of propofol were first studied in mice for identification of appropriate training doses in the propofol discrimination studies.
Methods

Subjects
Male Sprague-Dawley rats were obtained from Harlan-Sprague-Dawley (Indianapolis, Indiana, USA). All rats were housed individually and were maintained on a 12 h/ 12 h light/dark cycle. Body weights were maintained at 320-350 g by limiting food to 20 g/day. Water was freely available in the home cages. Male Swiss-Webster mice were obtained from Harlan at approximately 8 weeks of age and tested at approximately 10 weeks of age. Mice were group-housed in cages on a 12 h/12 h light/dark cycle and were allowed free access to food and water. All housing and procedures were approved by the University of North Texas Health Science Center Animal Care and Use Committee.
Locomotor activity
A Digiscan apparatus (model RXYZCM-16; Omnitech Electronics, Columbus, Ohio, USA) was used to measure ambulation within clear acrylic testing chambers (40.5 Â 40.5 Â 30.5 cm) that were housed in dimly lit sound-attenuating chambers. Separate groups of eight mice received either vehicle (2% methylcellulose) or propofol (3, 10, or 30 mg/kg) by intraperitoneal injection immediately before testing, and ambulation counts were recorded for 1 h.
Drug-discrimination procedures
Two-lever test chambers (Coulbourn Instruments, Allentown, Pennsylvania, USA), interfaces and computers programmed in MED-PC IV (Med Associates, East Fairfield, Vermont, USA) were used for the operation of the chambers and collection of data.
Groups of 16 rats were used for propofol discrimination training, one group at 5 mg/kg and another group at 10 mg/kg. An additional group of rats was trained to discriminate carisoprodol (100 mg/kg) from vehicle (2% methylcellulose). Food (45 mg food pellets; Bio-Serve, Frenchtown, New Jersey, USA) was available under a fixed-ratio 10 schedule of reinforcement when responding occurred on the injection-appropriate lever. Before each training session, the rats received an intraperitoneal injection of either vehicle (2% methylcellulose) or training drug. Twenty minutes after injection, the rats were placed in the experimental chamber for a 10-min session during which they could earn up to 20 food pellets. Subjects qualified for testing when they achieved 85% injection-appropriate responding for both the first reinforcer and total session in nine of ten training sessions.
Carisoprodol (100 mg/kg, 20 min pretreatment), chlordiazepoxide (10 mg/kg, 15 min), and dizocilpine (0.1 mg/kg, 15 min) were tested for substitution for propofol. Propofol was tested for substitution in carisoprodol-trained rats. The ability of pentylenetetrazol (10 mg/kg, 25 min) to block the discriminative-stimulus effects of propofol was also tested.
Drugs
All compounds were obtained from Sigma-Aldrich (St. Louis, Missouri, USA) and were administered intraperitoneally in a volume of 1 ml/kg. Propofol and carisoprodol were suspended in 2% methylcellulose. Chlordiazepoxide, dizocilpine, and pentylenetetrazol were dissolved in 0.9% saline.
Data analysis
Ambulation counts within 10-min periods were considered in a 4 Â 6 analysis of variance [Treatment Â Time (repeated)]. The 10 to 40-min time period was selected for analysis of dose-response data, because this was the period in which locomotor depression occurred. Ambulation counts from 10 to 40 min at each dose were compared with the vehicle control using individual F-tests, within the Treatment Â Time interaction.
Drug-appropriate responding and response rate data were analyzed by one-way repeated-measures analysis of variance. Individual doses were compared with the vehicle control using individual F-tests. Full substitution was defined as more than 80% drug-appropriate responding and partial substitution as 40% or more and less than 80% drug-appropriate responding and was not statistically different from the training drug. Survival data were analyzed using a Tarone-Ware w 2 -test. Mortality in the three groups (of 16 rats each; 10 mg/kg propofol group, 5 mg/kg propofol group, and carisoprodol group) was compared only during the training phase and during the testing of the training drug-dose effect (125 days). After this time, the three groups were tested with different drugs at different time points, which would potentially confound sources of mortality. The criterion for significance in all analyses was set a priori at P value of less than 0.05.
Results
Locomotor activity
The 30 mg/kg dose of propofol yielded depression of locomotor activity beginning after 10 min and lasting for approximately 30 min ( Fig. 1 ). Maximal depressant effects were evident during the period from 20 to 30 min after injection, and activity had returned to baseline after 40 min [F(15,135) = 3.94, P < 0.001; Treatment Â Time].
Discrimination
Drug-lever responding remained at chance levels for the group receiving 5 mg/kg propofol for 44 training sessions (22 drugs and 22 vehicles), so the training dose was increased to 10 mg/kg. Most subjects in both groups reached the training criterion within 60-70 sessions. The g-aminobutyric acid (GABA)-A receptor-positive modulators, carisoprodol and chlordiazepoxide, both partially substituted for the discriminative-stimulus effects of propofol (Table 1) . Dizocilpine failed to substitute for the discriminative-stimulus effects of propofol, but decreased the response rate [F(3,18) = 4.96, not significant]. The training dose of propofol did not depress rate of responding during training or during the subsequent substitution/antagonism tests. The GABA-A receptor antagonist, pentylenetetrazol, partially blocked the discriminative-stimulus effects of propofol without altering the response rate [F(1,1) = 0.03, not significant]. Propofol partially substituted in carisoprodol-trained rats without altering response rate [F(1,5) = 3.11, not significant]. Higher doses were not used because they depressed the response rates.
Survival
Substantial lethality was observed during these experiments (Fig. 2) . Three of 16 rats died during training in the 5 mg/kg group. Ten of 16 rats died during training in the 10 mg/kg group, whereas only one of 32 rats died during training in the carisoprodol-training group. A Tarone-Ware test indicated a significant effect [w 2 (2) = 8.38, P < 0.02]. Additional rats died after training, such that only eight of 32 propofol-trained rats completed testing. Accordingly, it was possible to test only single doses of each test compound in small groups of the surviving rats. Necropsy noted cardiomyocyte degeneration with inflammatory infiltrates and mineralization, and multifocal infiltrates of the foamy microphages in heart, spleen, and kidney. The lung showed diffuse congestion of the vessels and edematous multifocal alveoli consistent with cardiovascular collapse.
Discussion
The current studies used drug-discrimination training to establish a rat model of the psychoactive effects of subanesthetic doses of propofol. Doses up to 10 mg/kg failed to produce significant sedation in locomotoractivity studies in mice. Rats subsequently trained at this dose learned to discriminate propofol from saline and showed no evidence of sedation, as reflected in their rates of responding. A 5 mg/kg dose was not discriminable by the rats in this study, possibly indicating a relatively narrow dose range for a 'nonsedative' discriminative effect. The results are in accordance with other studies showing that centrally acting anesthetics are discriminable (e.g., Shelton, 2010; Shelton and Nicholson, 2010) .
Extensive testing of the pharmacological mechanisms of the propofol discriminative stimulus was not possible because of the high mortality produced by propofol. Compounds acting through GABA or N-methyl-d-aspartate (NMDA) receptors were tested at selected doses that yielded maximal effects in previous drug-discrimination studies without suppressing response rates: carisoprodol (100 mg/kg), chlordiazepoxide (10 mg/kg), pentylenetetrazol (10 mg/kg), and dizocilpine (0.1 mg/kg) (Gatch et al., 2005; Gatch and Pratt, 2006; Gonzalez et al., 2009) . The propofol discriminative stimulus was most similar to that of carisoprodol, a barbiturate-like compound (Gonzalez et al., 2009) , and to chlordiazepoxide, a benzodiazepine. Pentylenetetrazol, a GABA-A receptor antagonist, partially blocked the discriminative-stimulus effects of propofol. These findings are in agreement with earlier studies that propofol acts at GABA-A receptors Peduto et al., 1991) , and has discriminative-stimulus effects similar to muscimol (Jones and Balster, 1998) , although propofol does not substitute for midazolam (Ator, 2003) .
Although these findings suggest that the discriminativestimulus effects of propofol are mediated in part by the GABA-A receptor, propofol also binds to dopamine D2 and NMDA receptors (Schulte et al., 2000) . The NMDA receptor antagonist, dizocilpine, produced only 34% propofol-appropriate responding in this study. However, Effect of propofol on horizontal activity counts/10 min as a function of dose and time interval during a 60-min session. Individual comparisons with the vehicle group between the 10 and 40-min time period confirmed a significant depression only for the 30 mg/kg dose (*P < 0.05). 
mg/kg
Effect of propofol on survival as a function of time. Each group started with 16 rats each. The carisoprodol group was selected to act as a control because it was being trained at approximately the same time and because carisoprodol is suspended in the same vehicle as propofol (2% methylcellulose). The time period when the propofol 5 mg/kg group was switched to 10 mg/kg (arrow).
propofol modulated the effects of NMDA receptors in other studies (Orser et al., 1995; Li et al., 2008) , so further testing may reveal a glutamatergic component of the propofol discriminative stimulus.
The drug-discrimination training in this study exposed the rats only intermittently to nonsedating doses of propofol, yet produced considerable mortality over time.
The mortality was dose-dependent, as 10 mg/kg propofol produced substantially more mortality than 5 mg/kg propofol; however, switching to 10 mg/kg did not appear to increase mortality. The reason for this is not clear, but it is possible that gradually increasing the dose confers tolerance to the lethal effects. The propofol-associated mortality was not related to the vehicle (2% methylcellulose) or to the training of a sedative drug, per se, as the comparison group was matched on these characteristics.
It seems noteworthy that the cardiac myopathy and lung lesions observed in association with intermittent propofol at 10 mg/kg are consistent with abnormalities observed in propofol-infusion syndrome (PRIS), an often-fatal complication of extended propofol infusion in humans (Vasile et al., 2003; Zaccheo and Bucher, 2008; Riezzo et al., 2009) . PRIS is characterized by cardiac and renal failures, myopathies of both cardiac and skeletal muscles, and metabolic acidosis. Myocytic degeneration in PRIS has been linked to the ability of propofol to inhibit mitochondrial energy production in the heart and skeletal muscles, particularly when combined with glucocorticoids or catecholamines (Vasile et al., 2003; Zaccheo and Bucher, 2008) . As PRIS has been reported mainly in critically-ill patients requiring prolonged sedation, the causes of mortality observed in this study may differ. However, it is clear that abuse of propofol in humans is associated with a substantial risk of mortality (Wischmeyer et al., 2007) , and at least one case of PRIS has been reported (Riezzo et al., 2009) . Further, even though shortterm exposure to propofol produces neuroprotection, long-term exposure leads to increasing neurodegeneration in rat neuronal cultures (Berns et al., 2009) . It may be significant that it took approximately a month before mortality occurred in this study. Mortality was not reported in the conditioned place preference (Pain et al., 1996 (Pain et al., , 1997 , or self-administration (Weerts et al., 1999; LeSage et al., 2000; Blokhina et al., 2004) studies. It is possible that in these investigations, propofol was not administered for over a long period of time for significant problems to develop or warrant reporting.
Given that propofol produces a discriminable stimulus similar to known drugs of abuse, establishes a conditioned place preference (Pain et al., 1996 (Pain et al., , 1997 , and can be selfadministered (Weerts et al., 1999; LeSage et al., 2000; Blokhina et al., 2004) , there is evidence confirming its abuse liability in animal models. This evidence, coupled with its apparent toxicity when administered repeatedly, suggest that the potential for continued abuse of propofol should be of particular concern. Values that reached the criteria for partial substitution ( Z 40 and < 80% drug-appropriate responding, and was not statistically different from the training drug). b Response rates different from vehicle control.
